RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)
In a report released on January 7, Gregory Renza from RBC Capital maintained a Buy rating on Cormedix (CRMD – Research Report), with a price ...
Centerspace price target lowered to $72 from $76 at RBC Capital
RBC Capital analyst Brad Heffern lowered the firm’s price target on Centerspace (CSR) to $72 from $76 and keeps an Outperform ...
EconoTimes1d
RBC Upgrades Utilities Sector While Downgrading Energy
RBC Capital Markets has upgraded the Utilities sector to Overweight, naming it the top defensive sector, while downgrading ...
RBC Capital Sticks to Their Hold Rating for Moderna (MRNA)
In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Equity Lifestyle price target lowered to $69 from $72 at RBC Capital
RBC Capital lowered the firm’s price target on Equity Lifestyle (ELS) to $69 from $72 and keeps a Sector Perform rating on ...
Fertilizer market looks stable for 2025, RBC analysts say
Investors in fertilizer equities can expect steady prices and good cash generation, according to analysts at RBC Capital ...
Financial Services Roundup: Market Talk
Find insight on BBVA, Australia’s banks and more in the latest Market Talks covering Financial Services.
Top 30 global stock ideas from RBC Capital Markets analysts
The research team at RBC Capital Markets published their top 30 global stock ideas for 2025, ...
RBC Capital Remains a Buy on Nasdaq (NDAQ)
RBC Capital analyst Ashish Sabadra maintained a Buy rating on Nasdaq (NDAQ – Research Report) yesterday and set a price target of $95.00. The ...